3.675

2.38% -0.105

Adc Therapeutics Sa (ADCT)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

$3.78

Offen:

$3.76

24-Stunden-Volumen:

485.88K

Relative Volume:

0.63

Marktkapitalisierung:

$466.25M

Einnahmen:

$81.36M

Nettoeinkommen (Verlust:

$-142.62M

KGV:

-3.0602

EPS:

-1.2009

Netto-Cashflow:

$-146.97M

1W Leistung:

+1.37%

1M Leistung:

-10.22%

6M Leistung:

-16.70%

1J Leistung:

+212.71%

1-Tages-Spanne:

$3.67

$3.83

1-Wochen-Bereich:

$3.60

$3.97

52-Wochen-Spanne:

$1.05

$4.98

Adc Therapeutics Sa Stock (ADCT) Company Profile

Firmenname

Adc Therapeutics Sa

Sektor

Healthcare (1117)

Branche

Biotechnology (624)

Telefon

41 21 653 02 00

Adresse

BIOPOLE, EPALINGES

Mitarbeiter

193

Twitter

Nächster Verdiensttermin

2026-03-10

Neueste SEC-Einreichungen

ADCT's Discussions on Twitter

Compare ADCT vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ADCT Adc Therapeutics Sa	3.67	480.23M	81.36M	-142.62M	-146.97M	-1.2009
VRTX Vertex Pharmaceuticals Inc	433.58	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	762.40	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	747.05	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.89	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.74	35.01B	606.42M	-1.28B	-997.58M	-6.403

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-08	Eingeleitet	Stephens	Overweight
2024-05-30	Eingeleitet	Cantor Fitzgerald	Overweight
2024-03-28	Eingeleitet	Guggenheim	Buy
2023-08-10	Hochstufung	JP Morgan	Underweight → Neutral
2023-04-24	Herabstufung	BofA Securities	Neutral → Underperform
2022-12-06	Eingeleitet	CapitalOne	Overweight
2022-11-09	Herabstufung	BofA Securities	Buy → Neutral
2022-09-21	Eingeleitet	JP Morgan	Overweight
2022-09-09	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-11-09	Eingeleitet	Wolfe Research	Outperform
2021-08-17	Fortgesetzt	Jefferies	Buy
2021-08-09	Eingeleitet	RBC Capital Mkts	Outperform
2021-06-15	Eingeleitet	Cantor Fitzgerald	Overweight
2020-12-03	Eingeleitet	Stifel	Hold
2020-10-29	Eingeleitet	H.C. Wainwright	Buy
2020-06-09	Eingeleitet	BofA/Merrill	Buy
2020-06-09	Eingeleitet	Cowen	Outperform

Alle ansehen

Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten

Apr 05, 2026

Risk Off: Does ADC Therapeutics SA have a sustainable dividendWeekly Profit Analysis & Weekly Watchlist for Hot Stocks - baoquankhu1.vn

Apr 05, 2026

Insider Sell: What is the implied volatility of ADC Therapeutics SA2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

Next Generation Drug Conjugates (NDCs) Market Worth $42.55 Billion by 2035 | MarketsandMarkets - 富途牛牛

Apr 03, 2026

ADC Therapeutics delivers 70% return as Fair Value target hit - investing.com

Apr 03, 2026

Apr 02, 2026

Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells $8,641,179.68 in Stock - MarketBeat

Apr 02, 2026

Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells 196,229 Shares of Stock - MarketBeat

Apr 02, 2026

Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells 169,265 Shares of Stock - MarketBeat

Apr 02, 2026

Redmile-managed funds trim ADC Therapeutics (ADCT) stake with 5.9M-share sale - Stock Titan

Apr 02, 2026

ADCT.N Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 02, 2026

Apr 01, 2026

ADC Therapeutics Announces New Employee Inducement Grant - prnewswire.com

Apr 01, 2026

Mar 30, 2026

Energy Moves: Is ADC Therapeutics SA in a consolidation phase2026 Retail Activity & Real-Time Volume Spike Alerts - baoquankhu1.vn

Mar 30, 2026

ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance - MSN

Mar 30, 2026

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Mar 30, 2026

Mar 29, 2026

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update - Quantisnow

Mar 29, 2026

Mar 27, 2026

Nasdaq Moves: Is ADC Therapeutics SA a stock for growth or value investors2026 Setups & High Accuracy Buy Signal Tips - baoquankhu1.vn

Mar 27, 2026

Mar 26, 2026

ADC Therapeutics Eyes ZYNLONTA Expansion as LOTIS-5 Data Nears at H.C. Wainwright Chat - MarketBeat

Mar 26, 2026

Mar 24, 2026

ADC Therapeutics (NYSE:ADCT) Shares Gap Up on Analyst Upgrade - Defense World

Mar 24, 2026

Mar 23, 2026

ADC Therapeutics (NYSE:ADCT) Price Target Raised to $8.00 - MarketBeat

Mar 23, 2026

Mar 18, 2026

ADC Therapeutics (ADCT) Reports 2025 Revenue of $73.6M With Cash Runway Into 2028 - Yahoo Finance

Mar 18, 2026

US Stocks Recap: Can ADC Therapeutics SA disrupt its industryRate Hike & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Mar 18, 2026

Heights Capital Management Inc. Has $1.31 Million Position in ADC Therapeutics SA $ADCT - MarketBeat

Mar 18, 2026

Growth Recap: Will ADC Therapeutics SA benefit from rate cuts2026 Dividend Review & Technical Entry and Exit Tips - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

Fed Watch: Is ADC Therapeutics SA stock showing strong momentumMarket Rally & AI Enhanced Market Trend Forecasts - baoquankhu1.vn

Mar 17, 2026

[EFFECT] ADC Therapeutics SA SEC Filing - Stock Titan

Mar 17, 2026

Mar 16, 2026

ADC Therapeutics (ADCT) registers 9.83M shares issuable on HCR warrants - Stock Titan

Mar 16, 2026

Mar 15, 2026

ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones - MSN

Mar 15, 2026

Mar 14, 2026